Efruxifermin improves fibrosis in patients with metabolic dysfunction-associated steatohepatitis
1. Efruxifermin 50 mg once-weekly significantly improved fibrosis at 96 weeks versus placebo. 2. MASH resolution without worsened fibrosis was ...
Tag: hepatology
Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis
1. Use of Sodium-Glucose Cotransporter 2 (SGLT-2) inhibitors among adults with cirrhosis receiving diuretic therapy was associated with lower incidence ...
Early acetaminophen use reduces mortality risk in patients with sepsis-associated encephalopathy
1. Administration of acetaminophen within 48h of intensive care unit admission was associated with reduced short- and long-term mortality in ...
Dapagliflozin may improve outcomes in patients with metabolic dysfunction-associated steatohepatitis
1. The use of dapagliflozin in patients with metabolic dysfunction-associated steatohepatitis (MASH) resulted in a higher proportion of improvement of ...
Mirum: Ctexli reduces cholesterol metabolite build-up in patients with cerebrotendinous xanthomatosis
Ctexli significantly reduced levels of two atypical cholesterol metabolites usually elevated in patients with cerebrotendinous xanthomatosis (CTX) compared to the ...
Durvalumab and bevacizumab plus chemoembolization improves progression-free survival in hepatocellular carcinoma
1. Progression-free survival was significantly greater in the durvalumab plus bevacizumab group compared to placebo. 2. Common treatment-related adverse events ...
Characterization of the increased incidence of alcohol-associated hepatitis noted in Ontario, Canada in past two decades
1. From 2002 to 2021, the incidence rate of alcohol-associated hepatitis in Ontario, Canada increased by 8% annually, with rates ...
Aligos Therapeutics: ALG-055009 reduces liver fatty deposits in patients with metabolic-dysfunction associated steatohepatitis (MASH)
ALG-055009, a thyroid hormone receptor agonist, significantly reduced liver fat in patients with MASH after 12 weeks of treatment. ALG-055009 ...
Liver transplantation plus chemotherapy improves survival in patients with unresectable colorectal liver metastases
1. 5-year survival was significantly greater in the liver transplantation plus chemotherapy group compared to chemotherapy alone. 2. Serious adverse ...
Poor sleep and elevation of liver function biomarkers may be predictive of liver cancer
1. Unhealthy sleep, as well elevations of liver enzymes and decreased levels of albumin and liver functional biomarkers, were significantly ...
